Group 1 - Masimo announced the final agreement to sell its Sound United audio business to Samsung's subsidiary Harman International for $350 million in cash, with potential adjustments [1] - The transaction is expected to be completed by the end of this year [1]

Company Performance - Masimo reported quarterly earnings of $1.36 per share, exceeding the Zacks Consensus Estimate of $1.24 per share, and up from $0.77 per share a year ago, representing an earnings surprise of 9.68% [1] - The company posted revenues of $372 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.29%, but down from $492.8 million year-over-year [2] - Over the last four quarters, Masimo has consistently surpassed consensus EPS and revenue estimates [2] Future Outlook - The sustainability of Masimo's stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.27 on revenues of $372.12 million, and for the current fiscal year, it is $5.28 on revenues of $1.52 billion [7] - The estimate revisions trend for Masimo is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which Masimo belongs, is currently ranked in the top 25% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Data and Key Metrics Changes - The company reported Healthcare revenue of $371 million, reflecting a 10% growth on a constant currency basis, with operating margin expansion of 750 basis points [9][18] - Non-GAAP earnings per share (EPS) was $1.36, representing a 56% growth year-over-year, while GAAP net income from continuing operations was $47 million or $0.86 per share [19][20] - The net loss from discontinued operations was $218 million or $4.4 per share, including an impairment charge of $295 million related to the Audio business [20] Business Line Data and Key Metrics Changes - Consumable and service revenue grew by 8%, while capital equipment and other revenue surged by 32% due to the timing of shipments related to a large tender contract renewal [18] - The company shipped over 72,000 technology boards and monitors during the quarter, exceeding expected ranges [18] Market Data and Key Metrics Changes - The company anticipates revenue growth for fiscal 2025 to be in the range of $1.5 billion to $1.53 billion, reflecting an 8% to 11% constant currency growth compared to the previous year [20][21] - The updated guidance for operating margins is set at 28% to 28.5% excluding new tariffs, with EPS guidance of $5.3 to $5.6 [21] Company Strategy and Development Direction - The company plans to invest in its core Healthcare business to accelerate revenue growth beyond the long-standing target of 7% to 10% [13] - Strategic initiatives include upgrading existing sensors, leveraging leadership in pulse oximetry, and restructuring sales forces to be regionally focused [14] - The divestiture of the Consumer Audio business is aimed at refocusing on the Professional Healthcare business and enhancing shareholder value [10][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong performance and the ability to navigate macro uncertainties, highlighting the high recurring revenue and durable growth profile [16] - The CEO emphasized the commitment to innovation and the potential for improvement in commercial excellence [8][9] Other Important Information - The company is actively assessing the impact of potential tariffs and has developed mitigation plans to address these challenges [15][22] - A new Chief Human Resources Officer has joined the team to enhance company culture and talent development [11] Q&A Session Summary Question: Impact of large tender on revenues and margins - Management indicated that excluding the large tender, the rest of the business is performing well, with double-digit growth in consumables and services [29][30] Question: Future sales expectations - Management expects normal seasonality, with Q2 typically being flat to slightly down sequentially [32] Question: Long-term operating margin goals amid tariffs - Management remains confident in achieving long-term margin goals despite tariff impacts, with ongoing plans to mitigate these effects [42][43] Question: Use of proceeds from the sale of Sound United - The company plans to prioritize share repurchases with the proceeds from the sale, reflecting a focus on returning value to shareholders [47] Question: Hospital CapEx spending and demand - Management noted strong underlying demand and no signs of softness in the market, emphasizing the low dependency on capital equipment revenue [52] Question: Mitigation options for tariffs - Management is evaluating near-term and long-term mitigation strategies, including altering product sourcing and pricing opportunities [56][58] Question: Hemodynamic monitoring market potential - The company aims to enhance its presence in the hemodynamic monitoring market with new product launches planned for 2026 [66][68]

First Quarter 2025 Earnings May 6, 2025 3 1 Safe Harbor Statement Forward-Looking Statements: This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, statements about our expectations, plans, strategies or prospects. We generally use the words "may," "will," "expect," "believe," "anticipate," "plan," "estimate," "project," "assume," "guide," "target," "forecast," "see," "seek," "can," "should," "could," "would," "intend," "predict," "pote ...

Financial Data and Key Metrics Changes - The company reported Healthcare revenue of $371 million, reflecting a 10% growth on a constant currency basis, with operating margin expanding by 750 basis points [9][19] - Non-GAAP earnings per share (EPS) was $1.36, representing a 56% increase compared to the previous year [20] - The gross margin improved to 63.1%, an increase of 80 basis points year over year, while operating margin reached 28.8%, up 750 basis points year over year [20] Business Line Data and Key Metrics Changes - Consumable and service revenue grew by 8%, while capital equipment and other revenue surged by 32% [19] - The company shipped over 72,000 technology boards and monitors during the quarter, exceeding expectations due to strong core business performance [19] Market Data and Key Metrics Changes - The company anticipates revenue for fiscal 2025 to remain unchanged at a range of $1.5 billion to $1.53 billion, indicating an 8% to 11% constant currency growth compared to the prior year [21] - The impact of tariffs is projected to affect operating margins by 210 to 250 basis points and EPS by $0.45 to $0.50 [22][23] Company Strategy and Development Direction - The company aims to invest in its core Healthcare business to accelerate revenue growth beyond the long-standing target of 7% to 10% [13] - Plans include upgrading existing sensors and creating next-generation monitors with AI-based algorithms, leveraging leadership in pulse oximetry, and restructuring sales forces to be regionally focused [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong performance and ability to navigate macro uncertainties, highlighting the high recurring revenue and durable growth profile [16] - The CEO emphasized the commitment to innovation and the potential for improvement in commercial excellence [8][9] Other Important Information - The company announced the divestiture of its Consumer Audio business, Sound United, to refocus on its Professional Healthcare business [10][11] - A new Chief Human Resources Officer, Lisa Hellman, has joined the company to enhance culture and talent development [11] Q&A Session Summary Question: Impact of large tender on revenues and margins - Management clarified that excluding the large tender, the rest of the business is performing well, with double-digit growth in consumables and services [31][32] Question: Future sales expectations - Management indicated that Q2 is typically flat to slightly down sequentially, but they expect to maintain strong demand [35] Question: Long-term impact of tariffs on operating margins - Management remains optimistic about underlying business performance and expects to mitigate tariff impacts through various plans [45] Question: Valuation from the sale of Sound United - Management confirmed that the sale price was in line with expectations and that proceeds will primarily be used for share repurchases [49] Question: Hospital CapEx spending and OEM partners - Management noted strong underlying demand and low dependency on capital equipment, indicating no signs of softness in the market [54] Question: Mitigation options for tariffs - Management is evaluating near-term and long-term mitigation strategies, including altering product sourcing and pricing opportunities [59][60] Question: Changes in salesforce model - Management explained the shift to a generalist salesforce model to leverage broader knowledge across product categories, aiming for increased efficiency [88][89]

Exhibit 99.1 Irvine, California, May 6, 2025 - Masimo Corporation (Nasdaq: MASI) today announced its financial results for the first quarter ended March 29, 2025. First Quarter 2025 Results From Continuing Operations : (1) First Quarter 2025 Results From Discontinued Operations : (2) Masimo Reports First Quarter 2025 Results ■ GAAP loss from discontinued operations, net of tax was ($218) million, which included an impairment of intangibles of $295 million for the non-healthcare consumer business. Katie Szym ...

Core Insights - The Medical sector is expected to see double-digit earnings growth in 2025, driven by strong product revenues and growing demand, despite geopolitical issues and a stronger U.S. dollar impacting costs for domestic companies [1][4]. Earnings Overview - As of April 30, 45% of Medical sector companies, representing 57.9% of the sector's market capitalization, reported earnings, with 66.7% exceeding earnings and revenue estimates. Year-over-year earnings increased by 85.2% on a revenue increase of 70.4% [3]. - First-quarter 2025 earnings for the Medical sector are projected to improve by 40% with an 8.3% sales increase, compared to 13.4% earnings growth and 9.4% revenue growth in the previous quarter [4]. MedTech Trends - The adoption of generative AI and digital therapies is enhancing patient-friendly services, driven by an aging population and increased healthcare awareness, creating new revenue opportunities for MedTech companies [5]. - Despite positive trends, challenges such as macroeconomic uncertainties, supply-chain disruptions, and labor shortages may have impacted the sector's performance [6]. Company-Specific Insights - **Fresenius Medical Care**: Expected to report revenues of $5.25 billion with an EPS estimate of 43 cents, benefiting from the FME25 transformation program, but facing challenges from high U.S. dialysis patient mortality and labor cost inflation [8][9]. - **Masimo Corporation**: Anticipated to report revenues of $367.3 million and an EPS of $1.24, supported by strong performance across major product platforms and manufacturing efficiencies [10][11]. - **Clover Health**: Projected to report revenues of $476.9 million with a loss per share estimate of 7 cents, driven by strong member retention and growth in Medicare Advantage membership, though facing near-term margin pressures due to rapid expansion [12][13].

Core Insights - Masimo (MASI) has consistently surpassed earnings estimates, averaging a beat of 18.74% over the last two quarters [1][5] - In the most recent quarter, Masimo reported earnings of $1.80 per share, exceeding the expected $1.49 per share by 20.81% [2] - The previous quarter also saw Masimo outperforming estimates, reporting $0.98 per share against an expectation of $0.84 per share, a surprise of 16.67% [2] Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Masimo, with a positive Zacks Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5][8] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6] - Masimo currently holds an Earnings ESP of +0.64%, suggesting analysts are optimistic about the company's earnings prospects [8] Zacks Rank and Earnings ESP - The combination of a positive Earnings ESP and a Zacks Rank 1 (Strong Buy) indicates a high probability of another earnings beat for Masimo [8] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7] - A negative Earnings ESP does not necessarily indicate an earnings miss, but it reduces the predictive power of the metric [8]

Company Overview - Masimo Corporation (MASI) is positioned as an intriguing investment choice within the Medical - Instruments sector, supported by solid earnings estimate revisions [1][3]. - The company has experienced a positive shift in earnings estimates, indicating a more bullish outlook from analysts regarding its short and long-term prospects [3]. Industry Context - The Medical - Instruments industry currently holds a Zacks Industry Rank of 66 out of over 250 industries, suggesting a favorable position compared to other sectors [2]. - The industry is experiencing broad trends that are positively impacting securities across the board, indicating a rising tide effect [2]. Earnings Estimates - Over the past month, Masimo's current quarter earnings estimates have increased from $1.17 per share to $1.24 per share, while current year estimates have risen from $5.07 per share to $5.28 per share [4]. - These revisions have contributed to Masimo earning a Zacks Rank 1 (Strong Buy), highlighting the company's strong market position [4]. Investment Consideration - Given the strong performance of the industry and the positive earnings revisions, Masimo is recommended as a compelling option for investors seeking opportunities in a robust industry segment [5].

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? ...